According to CoinMeta, Yingpai Pharmaceutical (07630. hk) announced that in the first half of 2026, it generated revenue of 105 million yuan, a year-on-year increase of 316.8%. During this period, it incurred a loss of 90.81 million yuan. In the same period of 2025, the loss was 129 million yuan, and after adjustments, the net loss was 20.867 million yuan. In 2025, the loss for the same period was 55.841 million yuan. The company has established an exclusive cooperation with pharmanova, granting them the exclusive rights to manufacture, develop, and commercialize Senapali in Europe, the Middle East, North Africa, Australia, and New Zealand. The total amount of upfront payments and milestone payments related to this agreement amounts to up to 424 million euros.